International consensus guidance for management of myasthenia gravis

Executive summary

Donald B. Sanders, Gil I. Wolfe, Michael G Benatar, Amelia Evoli, Nils E. Gilhus, Isabel Illa, Nancy Kuntz, Janice M. Massey, Arthur Melms, Hiroyuki Murai, Michael Nicolle, Jacqueline Palace, David P. Richman, Jan Verschuuren, Pushpa Narayanaswami

Research output: Contribution to journalReview article

145 Citations (Scopus)

Abstract

Objective: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input. Results: Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. Conclusion: This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.

Original languageEnglish (US)
Pages (from-to)419-425
Number of pages7
JournalNeurology
Volume87
Issue number4
DOIs
StatePublished - Jul 26 2016

Fingerprint

Myasthenia Gravis
Consensus
Thymectomy
Plasma Exchange
Intravenous Immunoglobulins
Muscle Weakness
Postal Service
Advisory Committees
Therapeutics
Immunosuppressive Agents
Protein-Tyrosine Kinases
Pregnancy
Muscles
Antibodies

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Sanders, D. B., Wolfe, G. I., Benatar, M. G., Evoli, A., Gilhus, N. E., Illa, I., ... Narayanaswami, P. (2016). International consensus guidance for management of myasthenia gravis: Executive summary. Neurology, 87(4), 419-425. https://doi.org/10.1212/WNL.0000000000002790

International consensus guidance for management of myasthenia gravis : Executive summary. / Sanders, Donald B.; Wolfe, Gil I.; Benatar, Michael G; Evoli, Amelia; Gilhus, Nils E.; Illa, Isabel; Kuntz, Nancy; Massey, Janice M.; Melms, Arthur; Murai, Hiroyuki; Nicolle, Michael; Palace, Jacqueline; Richman, David P.; Verschuuren, Jan; Narayanaswami, Pushpa.

In: Neurology, Vol. 87, No. 4, 26.07.2016, p. 419-425.

Research output: Contribution to journalReview article

Sanders, DB, Wolfe, GI, Benatar, MG, Evoli, A, Gilhus, NE, Illa, I, Kuntz, N, Massey, JM, Melms, A, Murai, H, Nicolle, M, Palace, J, Richman, DP, Verschuuren, J & Narayanaswami, P 2016, 'International consensus guidance for management of myasthenia gravis: Executive summary', Neurology, vol. 87, no. 4, pp. 419-425. https://doi.org/10.1212/WNL.0000000000002790
Sanders, Donald B. ; Wolfe, Gil I. ; Benatar, Michael G ; Evoli, Amelia ; Gilhus, Nils E. ; Illa, Isabel ; Kuntz, Nancy ; Massey, Janice M. ; Melms, Arthur ; Murai, Hiroyuki ; Nicolle, Michael ; Palace, Jacqueline ; Richman, David P. ; Verschuuren, Jan ; Narayanaswami, Pushpa. / International consensus guidance for management of myasthenia gravis : Executive summary. In: Neurology. 2016 ; Vol. 87, No. 4. pp. 419-425.
@article{82c0a07660824e589bab62636eacceeb,
title = "International consensus guidance for management of myasthenia gravis: Executive summary",
abstract = "Objective: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input. Results: Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. Conclusion: This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.",
author = "Sanders, {Donald B.} and Wolfe, {Gil I.} and Benatar, {Michael G} and Amelia Evoli and Gilhus, {Nils E.} and Isabel Illa and Nancy Kuntz and Massey, {Janice M.} and Arthur Melms and Hiroyuki Murai and Michael Nicolle and Jacqueline Palace and Richman, {David P.} and Jan Verschuuren and Pushpa Narayanaswami",
year = "2016",
month = "7",
day = "26",
doi = "10.1212/WNL.0000000000002790",
language = "English (US)",
volume = "87",
pages = "419--425",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - International consensus guidance for management of myasthenia gravis

T2 - Executive summary

AU - Sanders, Donald B.

AU - Wolfe, Gil I.

AU - Benatar, Michael G

AU - Evoli, Amelia

AU - Gilhus, Nils E.

AU - Illa, Isabel

AU - Kuntz, Nancy

AU - Massey, Janice M.

AU - Melms, Arthur

AU - Murai, Hiroyuki

AU - Nicolle, Michael

AU - Palace, Jacqueline

AU - Richman, David P.

AU - Verschuuren, Jan

AU - Narayanaswami, Pushpa

PY - 2016/7/26

Y1 - 2016/7/26

N2 - Objective: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input. Results: Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. Conclusion: This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.

AB - Objective: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input. Results: Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. Conclusion: This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.

UR - http://www.scopus.com/inward/record.url?scp=84980368667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980368667&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000002790

DO - 10.1212/WNL.0000000000002790

M3 - Review article

VL - 87

SP - 419

EP - 425

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -